Abeona Therapeutics Earnings Report Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy ABEO?
Source: seekingalpha
- Earnings Performance: Abeona Therapeutics reported a FY GAAP EPS of $1.01, missing expectations by $0.17, indicating challenges in profitability that could impact investor confidence moving forward.
- Revenue Growth: Despite the EPS miss, the company achieved revenues of $5.82 million, surpassing market expectations of $5.22 million, demonstrating resilience in sales that may lay a foundation for future growth.
- Market Reaction: The EPS miss may put downward pressure on Abeona's stock price, prompting investors to monitor subsequent market dynamics and potential strategic adjustments to assess long-term investment value.
- Future Outlook: The company needs to implement measures to improve profitability, particularly in R&D and marketing, to enhance competitiveness and attract more investor interest, ensuring sustainable growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABEO
Wall Street analysts forecast ABEO stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.290
Low
20.00
Averages
25.17
High
28.00
Current: 4.290
Low
20.00
Averages
25.17
High
28.00
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abeona Therapeutics Q4 2025 Earnings Call Highlights
- Growing Patient Demand: Following the launch of ZEVASKYN in Q4 2025, the number of eligible patients surged from nearly 50 to over 100, indicating strong market demand that is expected to drive revenue growth and enhance competitive positioning.
- Improved Financial Performance: Total revenue for 2025 reached $5.8 million, with product revenue at $2.4 million and net income of $71.2 million, marking a shift from previous net losses to profitability, reflecting the effectiveness of the company's business model and market acceptance.
- Decreased R&D Spending: R&D expenses fell to $26.8 million in 2025 from $34.4 million in 2024, a reduction of $7.6 million primarily due to the FDA approval of ZEVASKYN and the subsequent shift of certain costs to inventory, showcasing the company's success in cost management.
- Expansion Plans: Management aims to activate at least 7 qualified treatment centers by the end of 2026 to ensure geographic coverage expansion, with expectations that treating over 3 patients per month will lead the company into profitability, further solidifying its market position.
See More
Abeona Therapeutics Launches Zivasskin Therapy Amid Growing Demand
- Growing Patient Demand: Abeona Therapeutics has seen increasing demand for Zivasskin, the first autologous cell-based gene therapy for RDE, with plans to ramp up its launch in 2026, enhancing its market share in the rare disease sector.
- Insurance Coverage Policies: Major commercial payers, including UnitedHealthcare and Cigna, have published coverage policies for Zivasskin, facilitating quicker patient access to treatment and potentially driving sales growth.
- Strong Financial Performance: The company recorded a $152.4 million gain from the sale of its rare pediatric disease priority review voucher, contributing to a net income of $71.2 million for 2025, reflecting a solid financial foundation and future growth potential.
- Operational Challenges: Despite the positive outlook for Zivasskin's launch, the lengthy onboarding process for Qualified Treatment Centers and variability in production timelines may hinder timely patient treatment, necessitating improvements in operational efficiency to meet market demand.
See More
Abeona (ABEO) Q4 2025 Earnings Call Transcript
See More
Abeona Therapeutics Earnings Report Analysis
- Earnings Performance: Abeona Therapeutics reported a FY GAAP EPS of $1.01, missing expectations by $0.17, indicating challenges in profitability that could impact investor confidence moving forward.
- Revenue Growth: Despite the EPS miss, the company achieved revenues of $5.82 million, surpassing market expectations of $5.22 million, demonstrating resilience in sales that may lay a foundation for future growth.
- Market Reaction: The EPS miss may put downward pressure on Abeona's stock price, prompting investors to monitor subsequent market dynamics and potential strategic adjustments to assess long-term investment value.
- Future Outlook: The company needs to implement measures to improve profitability, particularly in R&D and marketing, to enhance competitiveness and attract more investor interest, ensuring sustainable growth.
See More
Abeona Therapeutics to Announce FY Earnings on March 17
- Earnings Announcement: Abeona Therapeutics is set to release its FY earnings report on March 17 before the market opens, drawing attention to its performance and future outlook.
- EPS Expectations: The consensus EPS estimate stands at -$0.37, representing a significant year-over-year improvement of 76.1%, indicating potential financial performance recovery for the company.
- Revenue Forecast: Analysts project revenue to reach $5.22 million, reflecting the company's sales growth potential in the market, which could positively impact its stock price.
- Historical Financial Data: Historical earnings data for Abeona Therapeutics will provide investors with crucial context to assess performance changes and future strategic directions.
See More
Abeona Launches First Gene Therapy ZEVASKYN for RDEB
- FDA-Approved Innovation: Abeona Therapeutics has launched ZEVASKYN (prademagene zamikeracel), the first autologous gene therapy for treating recessive dystrophic epidermolysis bullosa (RDEB), marking a significant breakthrough in addressing severe skin diseases and is expected to greatly improve patients' quality of life.
- Increased Market Acceptance: ZEVASKYN has secured coverage from major commercial payers, including United Healthcare, Cigna, and Aetna, covering 80% of lives, indicating strong early market acceptance and anticipated sustained demand growth for the therapy.
- Manufacturing and Treatment Progress: Since resuming production in January 2026, Abeona has completed multiple biopsies and successfully treated patients, demonstrating positive advancements in establishing a stable treatment process and patient influx, which is expected to further enhance market confidence.
- Coding System Established: The CMS has established a permanent HCPCS J-code (J3389) for ZEVASKYN effective January 1, 2026, which will streamline medical billing and reimbursement processes, further promoting the therapy's market adoption and application.
See More
Abeona Therapeutics Q4 2025 Earnings Call Highlights
- Growing Patient Demand: Following the launch of ZEVASKYN in Q4 2025, the number of eligible patients surged from nearly 50 to over 100, indicating strong market demand that is expected to drive revenue growth and enhance competitive positioning.
- Improved Financial Performance: Total revenue for 2025 reached $5.8 million, with product revenue at $2.4 million and net income of $71.2 million, marking a shift from previous net losses to profitability, reflecting the effectiveness of the company's business model and market acceptance.
- Decreased R&D Spending: R&D expenses fell to $26.8 million in 2025 from $34.4 million in 2024, a reduction of $7.6 million primarily due to the FDA approval of ZEVASKYN and the subsequent shift of certain costs to inventory, showcasing the company's success in cost management.
- Expansion Plans: Management aims to activate at least 7 qualified treatment centers by the end of 2026 to ensure geographic coverage expansion, with expectations that treating over 3 patients per month will lead the company into profitability, further solidifying its market position.
See More
Abeona Therapeutics Launches Zivasskin Therapy Amid Growing Demand
- Growing Patient Demand: Abeona Therapeutics has seen increasing demand for Zivasskin, the first autologous cell-based gene therapy for RDE, with plans to ramp up its launch in 2026, enhancing its market share in the rare disease sector.
- Insurance Coverage Policies: Major commercial payers, including UnitedHealthcare and Cigna, have published coverage policies for Zivasskin, facilitating quicker patient access to treatment and potentially driving sales growth.
- Strong Financial Performance: The company recorded a $152.4 million gain from the sale of its rare pediatric disease priority review voucher, contributing to a net income of $71.2 million for 2025, reflecting a solid financial foundation and future growth potential.
- Operational Challenges: Despite the positive outlook for Zivasskin's launch, the lengthy onboarding process for Qualified Treatment Centers and variability in production timelines may hinder timely patient treatment, necessitating improvements in operational efficiency to meet market demand.
See More
Abeona (ABEO) Q4 2025 Earnings Call Transcript
See More
Abeona Therapeutics Earnings Report Analysis
- Earnings Performance: Abeona Therapeutics reported a FY GAAP EPS of $1.01, missing expectations by $0.17, indicating challenges in profitability that could impact investor confidence moving forward.
- Revenue Growth: Despite the EPS miss, the company achieved revenues of $5.82 million, surpassing market expectations of $5.22 million, demonstrating resilience in sales that may lay a foundation for future growth.
- Market Reaction: The EPS miss may put downward pressure on Abeona's stock price, prompting investors to monitor subsequent market dynamics and potential strategic adjustments to assess long-term investment value.
- Future Outlook: The company needs to implement measures to improve profitability, particularly in R&D and marketing, to enhance competitiveness and attract more investor interest, ensuring sustainable growth.
See More
Abeona Therapeutics to Announce FY Earnings on March 17
- Earnings Announcement: Abeona Therapeutics is set to release its FY earnings report on March 17 before the market opens, drawing attention to its performance and future outlook.
- EPS Expectations: The consensus EPS estimate stands at -$0.37, representing a significant year-over-year improvement of 76.1%, indicating potential financial performance recovery for the company.
- Revenue Forecast: Analysts project revenue to reach $5.22 million, reflecting the company's sales growth potential in the market, which could positively impact its stock price.
- Historical Financial Data: Historical earnings data for Abeona Therapeutics will provide investors with crucial context to assess performance changes and future strategic directions.
See More
Abeona Launches First Gene Therapy ZEVASKYN for RDEB
- FDA-Approved Innovation: Abeona Therapeutics has launched ZEVASKYN (prademagene zamikeracel), the first autologous gene therapy for treating recessive dystrophic epidermolysis bullosa (RDEB), marking a significant breakthrough in addressing severe skin diseases and is expected to greatly improve patients' quality of life.
- Increased Market Acceptance: ZEVASKYN has secured coverage from major commercial payers, including United Healthcare, Cigna, and Aetna, covering 80% of lives, indicating strong early market acceptance and anticipated sustained demand growth for the therapy.
- Manufacturing and Treatment Progress: Since resuming production in January 2026, Abeona has completed multiple biopsies and successfully treated patients, demonstrating positive advancements in establishing a stable treatment process and patient influx, which is expected to further enhance market confidence.
- Coding System Established: The CMS has established a permanent HCPCS J-code (J3389) for ZEVASKYN effective January 1, 2026, which will streamline medical billing and reimbursement processes, further promoting the therapy's market adoption and application.
See More
